Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neovascularization in idiopathic pulmonary fibrosis: too much or too little?

× No keyword cloud information.

16 in total

1. Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients.

Authors: Alessandro Giuseppe Fois; Anna Maria Posadino; Roberta Giordo; Annalisa Cossu; Abdelali Agouni; Nasser Moustafa Rizk; Pietro Pirina; Ciriaco Carru; Angelo Zinellu; Gianfranco Pintus
Journal: Oxid Med Cell Longev Date: 2018-10-21 Impact factor: 6.543

2. Effects of nintedanib on the microvascular architecture in a lung fibrosis model.

Authors: Maximilian Ackermann; Yong Ook Kim; Willi L Wagner; Detlef Schuppan; Cristian D Valenzuela; Steven J Mentzer; Sebastian Kreuz; Detlef Stiller; Lutz Wollin; Moritz A Konerding
Journal: Angiogenesis Date: 2017-03-10 Impact factor: 9.596

3. Different activity of the biological axis VEGF-Flt-1 (fms-like tyrosine kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: a bronchoalveolar lavage study.

Authors: Katerina M Antoniou; Giannoula Soufla; Athanasia Proklou; George Margaritopoulos; Christiana Choulaki; Rena Lymbouridou; Katerina D Samara; Demetrios A Spandidos; Nikolaos M Siafakas
Journal: Clin Dev Immunol Date: 2010-02-14

4. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis.

Authors: Naozumi Hashimoto; Sem H Phan; Kazuyoshi Imaizumi; Masaki Matsuo; Harunori Nakashima; Tsutomu Kawabe; Kaoru Shimokata; Yoshinori Hasegawa
Journal: Am J Respir Cell Mol Biol Date: 2009-09-18 Impact factor: 6.914

5. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.

Authors: Laszlo Farkas; Daniela Farkas; Kjetil Ask; Antje Möller; Jack Gauldie; Peter Margetts; Mark Inman; Martin Kolb
Journal: J Clin Invest Date: 2009-04-20 Impact factor: 14.808

Neovascularization in idiopathic pulmonary fibrosis: too much or too little?

1. Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients.

2. Effects of nintedanib on the microvascular architecture in a lung fibrosis model.

3. Different activity of the biological axis VEGF-Flt-1 (fms-like tyrosine kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: a bronchoalveolar lavage study.

4. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis.

5. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.

Review 6. Novel therapeutic approaches for pulmonary fibrosis.

Review 7. Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander?

Review 8. Clinical implications for vascular endothelial growth factor in the lung: friend or foe?

Review 9. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.

Review 10. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.